Company Overview
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Recent Developments
- Dec 2025 Revenue of $301.65K (+78.8% YoY); net profit $-8.22M.
- Trailing 12 Months Year-on-year growth — revenue -82.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -38.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -38.88% |
| 1 Year: | -82.80% |
Stock Price Performance
| 1 Year: | +471.60% |
| 6 Months: | -64.91% |
| 3 Months: | -68.19% |
| 1 Month: | -54.77% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)17.02 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -38.9% CAGR over 5 years.
- Trading 91.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 17 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NXL Nexalin Technology, Inc. PHARMA | 4.79 | -0.35 | $4.10M | 0.00% | - | - | -38.88% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55.97K | 323.32K | 414.29K | 545.32K | 30.56K | 35.54K | 24.11K | 78.67K | 26.84K | 36.03K | - | 41.02K | 70.59K | 18.15K | 171.90K | 14.95K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 13.56K | 22.84K | 3.95K | 21.03K | 1.82K |
| Gross Profit | 46.66K | 277.31K | 291.26K | 358.02K | 23.45K | 26.17K | 20.14K | 69.52K | 19.59K | 23.34K | - | 27.46K | 47.75K | 14.20K | 150.87K | 13.13K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 2.04M | 1.67M | 2.36M | 2.56M | 2.13M |
| Operating Income | -1.80M | -375.12K | -445.10K | -293.19K | -779.43K | -876.86K | -2.42M | -1.07M | -1.30M | -2.51M | - | -2.01M | -1.62M | -2.35M | -2.41M | -2.12M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -2.01M | -1.62M | -2.34M | -2.41M | -2.11M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -1.99M | -1.58M | -2.28M | -2.38M | -2.10M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -1.80M | -393.25K | -439.49K | -135.40K | -748.41K | -822.44K | -2.30M | -1.04M | -1.28M | -2.45M | - | -1.99M | -1.58M | -2.28M | -2.38M | -2.10M |
| Diluted EPS | - | - | -0.09 | -0.03 | -0.10 | -0.11 | -0.31 | -0.14 | -0.17 | -0.23 | - | -0.15 | -0.10 | -0.13 | - | -0.11 |
| R&D Expense | 33.47K | 11.56K | 29.54K | 113.62K | 65.83K | 146.00K | 1.64M | 105.67K | 169.41K | 178.56K | - | 406.29K | 225.77K | 226.52K | - | 346.38K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.32M | 110.75K | 168.72K | 301.65K |
| Cost of Revenue | - | 363.21K | 25.69K | 36.59K | 61.37K |
| Gross Profit | - | 958.14K | 85.06K | 132.13K | 240.27K |
| Operating Expenses | - | 2.79M | 5.78M | 7.89M | 8.63M |
| Operating Income | - | -1.83M | -5.70M | -7.75M | -8.39M |
| EBITDA | - | -1.83M | -5.69M | -7.74M | -8.37M |
| Interest Expense | 82.32K | 59.38K | - | - | - |
| Pretax Income | - | -1.70M | -4.65M | -7.61M | -8.22M |
| Tax Provision | - | - | 0 | 0 | 0 |
| Net Income | - | -1.70M | -4.65M | -7.61M | -8.22M |
| Diluted EPS | - | -0.30 | -0.63 | -0.83 | -0.50 |
| R&D Expense | 139.00K | 511.00K | 1.92M | 1.19M | 1.08M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 7.43M | 3.63M | 4.22M | 4.64M |
| Current Assets | - | - | 7.43M | 3.43M | 3.96M | 4.30M |
| Cash & Equivalents | - | - | 162.74K | 580.23K | 574.49K | 654.78K |
| Inventory | - | - | 154.37K | 156.42K | 174.58K | 131.47K |
| Receivables | - | - | 4.88K | 9.37K | 13.04K | 81.57K |
| Total Liabilities | - | - | 1.95M | 425.28K | 546.69K | 887.33K |
| Current Liabilities | - | - | 1.95M | 425.28K | 546.69K | 887.33K |
| Long Term Debt | - | 22.92K | - | - | - | - |
| Total Debt | - | 850.05K | 755.26K | 4.46K | 0 | - |
| Total Equity | -1.59M | - | 5.48M | 3.21M | 3.68M | 3.75M |
| Shares Outstanding | - | - | 7.29M | 7.44M | 13.30M | 19.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -2.22M | -3.84M | -3.94M | -4.96M |
| Investing Cash Flow | - | -6.79M | 4.45M | -577.54K | -131.99K |
| Financing Cash Flow | - | 8.51M | -200.00K | 4.52M | 5.17M |
| Capital Expenditure | - | - | -109.28K | -170.31K | -96.86K |
| Free Cash Flow | - | -2.22M | -3.94M | -4.11M | -5.05M |
| Net Change in Cash | - | -499.04K | 417.49K | -5.75K | 80.30K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 72.5% | 76.8% | 78.3% | 79.7% |
| Operating Margin % | - | -138.7% | -5,143.5% | -4,596.1% | -2,781.7% |
| Net Margin % | - | -128.5% | -4,197.6% | -4,508.7% | -2,725.8% |
| ROE % | - | -31.0% | -145.0% | -206.9% | -219.4% |
| ROCE % | - | -33.4% | -177.6% | -211.0% | -223.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Peak6 LLC | 0.04% | 8.01K | $39.23K |
| 2 | Geode Capital Management, LLC | 0.02% | 4.65K | $22.80K |
| 3 | Vanguard Capital Management LLC | 0.02% | 4.22K | $20.67K |
| 4 | Citadel Advisors Llc | 0.01% | 2.51K | $12.31K |
| 5 | Jane Street Group, LLC | 0.01% | 2.18K | $10.70K |
| 6 | Vanguard Fiduciary Trust Co | 0.01% | 1.71K | $8.39K |
| 7 | State Street Corporation | - | 1.08K | $5.28K |
| 8 | UBS Group AG | - | 894 | $4.38K |
| 9 | Northern Trust Corporation | - | 803 | $3.93K |
| 10 | Kovack Advisors, Inc. | - | 744 | $3.65K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NXL
Nexalin Technology Announces Reverse Stock Split
HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company’s common stock, to ensure c…
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
Study using Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results further validate Nexalin’s prior clinic…
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life
Nexalin Technology Inc. (NASDAQ:NXL) on Wednesday reported clinical trial results in Brazil. The trial showed improvements in anxiety, depression, insomnia, and quality-of-life measures, supporting its drug-free neurostimulation approach. A…
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin’s proprietary position in non-invasive frequency-based deep-brain neurostimulation Patent covers transcranial alt…
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSDHOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( (Nasdaq: NX…
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
Publication reports statistically significant improvement in sleep quality following treatment with Nexalin’s 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group Neuroimaging data provides mechanistic suppo…
NXL — Frequently Asked Questions
What is the current share price of Nexalin Technology, Inc. (NXL)?
As of 2026-09-19 21:16 PDT, Nexalin Technology, Inc. (NXL) trades at $4.79 on NasdaqCM. Its 52-week range is $0.72 to $55.80.
What is the market capitalisation of NXL?
Nexalin Technology, Inc. (NXL) has a market capitalisation of $4.10M on NasdaqCM.
What is the P/E ratio of NXL?
NXL trades at a trailing price-to-earnings (P/E) ratio of -0.35. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 71.01.
Is NXL a good stock to buy?
This page provides a data-driven analysis of Nexalin Technology, Inc. (NXL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.